Toxicity has been fatal about 10% of the time.Injury ismon with amiodarone, but is usually mild and evidenced only by abnormal liver enzymes.Liver disease can occur, however, and has been fatal in a few cases.Other antiarrhythmics, amiodarone can exacerbate the arrhythmia, e.By making the arrhythmia less well tolerated or more difficult to reverse.Has occurred in 2 to 5% of patients in various series, and significant heart block or sinus bradycardia has been seen in 2 to 5%.Of these events should be manageable in the proper clinical setting in most cases.The frequency of such proarrhythmic events does not appear greater with amiodarone than with many other agents used in this population, the effects are prolonged when they occur.Even in patients at high risk of arrhythmic death, in whom the toxicity of amiodarone is an acceptable risk, amiodarone poses major management problems that could be life-threatening in a population at risk of sudden death, so that every effort should be made to utilize alternative agents first.The difficulty of using amiodarone effectively and safely itself poses a significant risk to patients.With the indicated arrhythmias must be hospitalized while the loading dose of amiodarone is given, and a response generally requires at least one week, usually two or more.Absorption and elimination are variable, maintenance-dose selection is difficult, and it is not unusual to require dosage decrease or discontinuation of treatment.A retrospective survey of 192 patients with ventricular tachyarrhythmias, 84 required dose reduction and 18 required at least temporary discontinuation because of adverse effects, and several series have reported 15 to 20% overall frequencies of discontinuation due to adverse reactions.Time at which a previously controlled life-threatening arrhythmia will recur after discontinuation or dose adjustment is unpredictable, ranging from weeks to months.Patient is obviously at great risk during this time and may need prolonged hospitalization.To substitute other antiarrhythmic agents when amiodarone must be stopped will be made difficult by the gradually, but unpredictably, changing amiodarone body burden.Similar problem exists when amiodarone is not effective; it still poses the risk of an interaction with whatever subsequent treatment is tried.DESCRIPTION: Amiodarone Hydrochloride is a member of a new class of antiarrhythmic drugs with predominantly Class III (Vaughan Williams' classification) effects, available for oral administration as scored tablets containing 200 mg of amiodarone hydrochloride.Addition, each tablet also contains the following inactive ingredients: Colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, povidone, and sodium starch glycolate.Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes
Studies of liver function and hepatotoxic cases after treatment with triacetyloleandomycin and propionyl erythromycin ester lauryl sulfate
